RxDoctor Payments Data

Marlene Morales, MD

Ophthalmology · Tomball, TXNPI 1336349117

Payments from drug & device makers

$4,714in general payments, 2019–2025

Across 129 payments — averaging $36.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Alcon$455
  • Bausch & Lomb Americas Inc.$421
  • AbbVie$408
  • Oyster Point Pharma, Inc.$269
  • Aerie Pharmaceuticals, Inc.$187
  • plus $773 from 17 others

What the payments were for

  • Speaking & faculty fees$1,30528%
  • Food & beverage$3,38972%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,714 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$207,097
Medicare patients
502
Services billed
2,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine16$9,387
AzoptBrinzolamide12$6,337
RocklatanNetarsudil Mesylat/Latanoprost11$5,329
Latanoprost112$1,322
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha78$863
ErythromycinErythromycin Base60$590
Prednisolone Acetate16$462
Brimonidine Tartrate21$433
Timolol Maleate40$361
Doxycycline Hyclate26$302
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconAzopt$455$6,33712 claims
Aerie Pharmaceuticals, Inc.Rocklatan$187$5,32911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →